Apellis Free Cash Flow vs Free Cash Flow Yield Analysis

APLS Stock

USD 32.96 0.36 1.08%

Apellis Pharmaceuticals financial indicator trend analysis is way more than just evaluating Apellis Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Apellis Pharmaceuticals is a good investment. Please check the relationship between Apellis Pharmaceuticals Free Cash Flow and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Free Cash Flow vs Free Cash Flow Yield

Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Apellis Pharmaceuticals Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak relationship.

The correlation between Apellis Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield is 0.38. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Apellis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Apellis Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Apellis Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Free Cash Flow i.e., Apellis Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.38

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Apellis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Apellis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.At this time, Apellis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 1.63 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.5M	1.5M	1.7M	1.0M
Interest Income	418K	8.9M	20.9M	22.0M

Reconciled Depreciation Interest Income

Apellis Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Property Plant Equipment	Capital Surpluse
Total Assets		0.8	0.79	0.87	0.83	-0.86	-0.77	0.69	0.97	0.94	0.96	0.4	0.88	0.83	0.48	0.77	0.78	0.99	0.83	1.0	0.93	0.84	0.78	0.89	0.97	0.87
Other Current Liab	0.8		1.0	0.68	0.65	-0.73	-0.97	0.92	0.72	0.69	0.68	0.84	0.88	0.96	0.88	0.81	0.97	0.8	0.65	0.8	0.81	0.77	0.41	0.83	0.88	0.87
Total Current Liabilities	0.79	1.0		0.68	0.66	-0.75	-0.98	0.94	0.72	0.68	0.67	0.84	0.89	0.97	0.9	0.83	0.99	0.79	0.66	0.8	0.82	0.78	0.4	0.82	0.88	0.87
Total Stockholder Equity	0.87	0.68	0.68		0.85	-0.81	-0.69	0.65	0.84	0.75	0.82	0.38	0.87	0.73	0.46	0.68	0.71	0.79	0.85	0.87	0.89	0.95	0.65	0.77	0.77	0.82
Property Plant And Equipment Net	0.83	0.65	0.66	0.85		-0.83	-0.67	0.64	0.85	0.76	0.81	0.32	0.81	0.72	0.41	0.66	0.67	0.79	1.0	0.83	0.82	0.76	0.63	0.72	0.79	0.8
Net Debt	-0.86	-0.73	-0.75	-0.81	-0.83		0.8	-0.78	-0.93	-0.87	-0.82	-0.33	-0.87	-0.83	-0.53	-0.88	-0.81	-0.84	-0.83	-0.86	-0.92	-0.83	-0.74	-0.83	-0.86	-0.86
Retained Earnings	-0.77	-0.97	-0.98	-0.69	-0.67	0.8		-0.98	-0.71	-0.68	-0.62	-0.79	-0.86	-0.96	-0.92	-0.88	-1.0	-0.76	-0.67	-0.78	-0.84	-0.76	-0.42	-0.82	-0.86	-0.84
Accounts Payable	0.69	0.92	0.94	0.65	0.64	-0.78	-0.98		0.64	0.58	0.53	0.77	0.84	0.95	0.93	0.83	0.98	0.66	0.64	0.69	0.8	0.74	0.31	0.71	0.78	0.82
Cash	0.97	0.72	0.72	0.84	0.85	-0.93	-0.71	0.64		0.96	0.97	0.27	0.87	0.79	0.38	0.76	0.72	0.96	0.85	0.96	0.91	0.83	0.83	0.86	0.92	0.88
Non Current Assets Total	0.94	0.69	0.68	0.75	0.76	-0.87	-0.68	0.58	0.96		0.94	0.22	0.76	0.73	0.34	0.81	0.68	0.95	0.76	0.93	0.82	0.72	0.92	0.92	0.91	0.76
Cash And Short Term Investments	0.96	0.68	0.67	0.82	0.81	-0.82	-0.62	0.53	0.97	0.94		0.23	0.82	0.72	0.29	0.66	0.64	0.95	0.81	0.96	0.83	0.8	0.84	0.84	0.89	0.82
Net Receivables	0.4	0.84	0.84	0.38	0.32	-0.33	-0.79	0.77	0.27	0.22	0.23		0.63	0.74	0.91	0.52	0.8	0.39	0.32	0.41	0.48	0.52	-0.09	0.49	0.53	0.61
Common Stock Total Equity	0.88	0.88	0.89	0.87	0.81	-0.87	-0.86	0.84	0.87	0.76	0.82	0.63		0.93	0.68	0.75	0.89	0.84	0.81	0.89	0.93	0.94	0.52	0.8	0.88	0.99
Common Stock Shares Outstanding	0.83	0.96	0.97	0.73	0.72	-0.83	-0.96	0.95	0.79	0.73	0.72	0.74	0.93		0.84	0.83	0.97	0.82	0.72	0.83	0.88	0.82	0.46	0.82	0.9	0.93
Inventory	0.48	0.88	0.9	0.46	0.41	-0.53	-0.92	0.93	0.38	0.34	0.29	0.91	0.68	0.84		0.7	0.91	0.47	0.41	0.49	0.61	0.58	0.05	0.57	0.62	0.65
Other Current Assets	0.77	0.81	0.83	0.68	0.66	-0.88	-0.88	0.83	0.76	0.81	0.66	0.52	0.75	0.83	0.7		0.88	0.76	0.66	0.76	0.79	0.71	0.7	0.92	0.82	0.72
Other Stockholder Equity	0.78	0.97	0.99	0.71	0.67	-0.81	-1.0	0.98	0.72	0.68	0.64	0.8	0.89	0.97	0.91	0.88		0.76	0.67	0.78	0.84	0.8	0.42	0.82	0.86	0.86
Total Liab	0.99	0.8	0.79	0.79	0.79	-0.84	-0.76	0.66	0.96	0.95	0.95	0.39	0.84	0.82	0.47	0.76	0.76		0.79	0.99	0.9	0.77	0.78	0.88	0.98	0.85
Property Plant And Equipment Gross	0.83	0.65	0.66	0.85	1.0	-0.83	-0.67	0.64	0.85	0.76	0.81	0.32	0.81	0.72	0.41	0.66	0.67	0.79		0.83	0.82	0.76	0.63	0.72	0.79	0.8
Total Current Assets	1.0	0.8	0.8	0.87	0.83	-0.86	-0.78	0.69	0.96	0.93	0.96	0.41	0.89	0.83	0.49	0.76	0.78	0.99	0.83		0.93	0.84	0.77	0.89	0.97	0.88
Common Stock	0.93	0.81	0.82	0.89	0.82	-0.92	-0.84	0.8	0.91	0.82	0.83	0.48	0.93	0.88	0.61	0.79	0.84	0.9	0.82	0.93		0.89	0.62	0.8	0.93	0.92
Net Tangible Assets	0.84	0.77	0.78	0.95	0.76	-0.83	-0.76	0.74	0.83	0.72	0.8	0.52	0.94	0.82	0.58	0.71	0.8	0.77	0.76	0.84	0.89		0.57	0.78	0.77	0.9
Non Currrent Assets Other	0.78	0.41	0.4	0.65	0.63	-0.74	-0.42	0.31	0.83	0.92	0.84	-0.09	0.52	0.46	0.05	0.7	0.42	0.78	0.63	0.77	0.62	0.57		0.82	0.69	0.51
Other Assets	0.89	0.83	0.82	0.77	0.72	-0.83	-0.82	0.71	0.86	0.92	0.84	0.49	0.8	0.82	0.57	0.92	0.82	0.88	0.72	0.89	0.8	0.78	0.82		0.89	0.76
Property Plant Equipment	0.97	0.88	0.88	0.77	0.79	-0.86	-0.86	0.78	0.92	0.91	0.89	0.53	0.88	0.9	0.62	0.82	0.86	0.98	0.79	0.97	0.93	0.77	0.69	0.89		0.89
Capital Surpluse	0.87	0.87	0.87	0.82	0.8	-0.86	-0.84	0.82	0.88	0.76	0.82	0.61	0.99	0.93	0.65	0.72	0.86	0.85	0.8	0.88	0.92	0.9	0.51	0.76	0.89

Click cells to compare fundamentals

Apellis Pharmaceuticals Account Relationship Matchups

Apellis Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	389.2M	960.6M	881.8M	760.2M	788.7M	425.1M
Other Current Liab	54.8M	116.2M	110.8M	124.6M	203.6M	213.8M
Total Current Liabilities	65.8M	128.3M	131.8M	167.6M	247.6M	260.0M
Total Stockholder Equity	34.2M	204.6M	198.7M	169.9M	194.5M	118.8M
Net Debt	(195.0M)	(188.0M)	(430.0M)	(439.1M)	(240.3M)	(252.3M)
Retained Earnings	(581.5M)	(926.3M)	(1.7B)	(2.3B)	(2.8B)	(2.7B)
Accounts Payable	8.4M	8.5M	16.9M	37.3M	37.5M	39.4M
Cash	352.0M	565.8M	640.2M	551.8M	351.2M	289.2M
Non Current Assets Total	16.2M	43.4M	57.7M	40.7M	22.4M	18.2M
Cash And Short Term Investments	352.0M	877.6M	700.6M	551.8M	352.3M	326.5M
Common Stock Total Equity	5.0K	5.6K	6.4K	8K	9.2K	9.7K
Common Stock Shares Outstanding	62.2M	75.2M	84.4M	106.1M	118.7M	124.6M
Liabilities And Stockholders Equity	389.2M	960.6M	881.8M	760.2M	788.7M	425.1M
Other Current Assets	1.3M	14.5M	97.1M	73.0M	61.2M	64.3M
Other Stockholder Equity	615.8M	1.1B	1.9B	2.5B	3.0B	3.2B
Total Liab	355.0M	756.0M	683.1M	590.3M	594.2M	306.3M
Total Current Assets	373.1M	917.2M	824.0M	719.5M	766.3M	406.9M
Accumulated Other Comprehensive Income	(153.8K)	(117K)	(2.1M)	(875K)	(3.5M)	(3.4M)
Common Stock	6.4K	8K	10K	11K	12K	6.2K
Net Tangible Assets	34.2M	204.6M	198.7M	169.9M	195.4M	205.1M
Non Currrent Assets Other	385.1K	18.9M	31.6M	15.8M	1.3M	1.2M
Other Assets	385K	18.9M	31.6M	15.8M	18.2M	19.1M
Property Plant Equipment	15.8M	24.5M	26.1M	24.9M	28.6M	16.9M
Non Current Liabilities Total	289.3M	627.7M	551.3M	422.7M	346.6M	314.8M
Short Long Term Debt Total	157.0M	377.7M	210.2M	112.7M	110.9M	164.8M
Other Liab	134.8M	253.6M	345.2M	315.6M	363.0M	192.4M
Long Term Debt	142.6M	358.8M	189.0M	92.7M	93.0M	145.8M
Net Invested Capital	176.8M	563.4M	387.7M	262.6M	287.6M	320.8M
Net Working Capital	307.3M	788.9M	692.2M	551.9M	518.7M	506.0M
Short Term Debt	2.6M	3.7M	4.1M	5.6M	6.4M	5.8M
Capital Stock	6.4K	8K	10K	11K	12K	9.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC